IP Library Granted Patent US 11,389,467
Granted Patent B2
US 11,389,467 · App. 16/945,067 · Granted Jul 19, 2022

Topical compositions

Inventors: Varsha Bhatt (San Francisco, CA); Radhakrishnan Pillai (Santa Rosa, CA); Arturo Angel (Santa Rosa, CA)
Assignee: BAUSCH HEALTH IRELAND LIMITED
A61K31/7056A61K9/0014A61K9/06A61K31/192A61K31/327A61K47/02A61K47/10A61K47/32A61P17/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,467
App. No.
16/945,067
Granted
Jul 19, 2022
Kind
B2
Abstract

The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.

Claims (42)

1. A topical gel formulation comprising

active ingredients of 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with

a gelling agent,

an additional agent as a polyhydric alcohol, and

water,

wherein said benzoyl peroxide is not encapsulated or entrained in a microsponge.

2. The formulation of claim 1 , wherein the active ingredients comprise about 1.2 wt. % clindamycin phosphate, about 3.1 wt. % benzoyl peroxide, and about 0.15 wt. % adapalene.

3. The formulation of claim 2 , wherein the formulation comprises

a) about 1.2 wt. % clindamycin phosphate,

b) about 3.1 wt. % benzoyl peroxide,

c) about 0.15 wt. % adapalene,

d) about 5 wt. % propylene glycol,

e) about 1.75 wt. % carbomer homopolymer Type C,

f) potassium hydroxide in an amount to provide a pH of 5-6, and

g) water.

4. A method of treating an inflammatory skin condition in a patient in need thereof, comprising administering to an affected area of the skin on at least a daily basis, a topical gel formulation according to claim 1 .

5. The method of claim 4 , wherein the inflammatory skin condition is acne.

6. The method of claim 5 , wherein administration is once daily over a period of at least 4 weeks.

7. The method of claim 6 , wherein the treatment is more effective in treating acne than treatment with another formulation comprising active ingredients selected from the group consisting of (i) 1-1.5 wt. % clindamycin phosphate and 2.5-3.5 wt. % benzoyl peroxide, (ii) 2.5-3.5 wt. % benzoyl peroxide and 0.1-0.2 wt. % adapalene, and (iii) 1-1.5 wt. % clindamycin phosphate and 0.1-0.2 wt. % adapalene.

8. A drug container, comprising a pump and a topical gel formulation according to claim 1 , wherein the pump is calibrated to release a specific amount of the formulation each time the pump is pressed.

9. A method of making a topical gel formulation according to claim 1 , comprising

i) providing the following premixes:

a) Premix A comprising a dispersion of gelling agent in water,

b) Premix B comprising a dispersion of benzoyl peroxide in polyhydric alcohol and water,

c) Premix C comprising clindamycin phosphate in aqueous solution,

d) Premix D comprising a dispersion of micronized adapalene in polyhydric alcohol and water,

ii) mixing Premix A and Premix D,

iii) admixing Premix B to the mixture of step ii,

iv) admixing Premix C to the mixture of step iii, and

v) adjusting the pH of the mixture of step iv to pH 5-6 to form a gel.

10. The formulation of claim 1 , wherein the gelling agent is selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, carboxyvinyl polymers (crosslinked with allyl ethers of polyalcohols), carboxyvinyl copolymers, polyacrylates, acrylate copolymers, acrylamide/sodium acryloyldimethyltaurate copolymers, polyvinyl alcohols, polyethylene oxides, propylene glycol alginates, methylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan gum, and combinations thereof.

11. The formulation of claim 1 , wherein the gelling agent comprises carbomer homopolymer Type C.

12. The formulation of claim 1 , wherein the gelling agent is a crosslinked polymer comprising carboxy moieties and wherein the formulation further comprises a base selected from the group consisting of potassium hydroxide, sodium hydroxide and combinations thereof in an amount sufficient to deprotonate the carboxy moieties sufficiently to cause the gelling agent to thicken.

13. The formulation of claim 1 , wherein the amount of gelling agent is 5-2 wt. %.

14. The formulation of claim 1 , wherein a fraction of the benzoyl peroxide is undissolved and wherein the undissolved fraction of the benzoyl peroxide is homogeneously dispersed in the formulation.

15. The formulation of claim 14 , wherein the undissolved fraction of the benzoyl peroxide has a mean particle size between 1 and 50 microns.

16. The formulation of claim 14 , wherein a fraction of the adapalene is undissolved and wherein the undissolved fraction of the adapalene is homogeneously dispersed in the formulation.

17. The formulation of claim 1 , wherein the adapalene and the benzoyl peroxide do not undergo any detrimental interaction with one another.

18. The formulation of claim 1 , wherein the polyhydric alcohol is selected from propylene glycol, ethoxydiglycol, polyethylene glycol, glycerol, and combinations thereof.

19. The formulation of claim 1 , wherein the formulation is free of additional agents as organic solvents other than the polyhydric alcohol.

20. The formulation of claim 1 , wherein the amount of polyhydric alcohol is 3-7 wt. %.

21. The formulation of claim 1 , wherein the formulation is free of ionic surfactants.

Assignments (12)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2022
From: BHATT, VARSHA; PILLAI, RADHAKRISHNAN; ANGEL, ARTURO
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 060283/0428 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
SECURITY INTEREST Recorded Jan 21, 2021
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 054984/0345 →
SECURITY INTEREST Recorded Jan 21, 2021
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 054984/0324 →
Cited By (1)
US 12,616,710